
Cellebrite DI (CLBT) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
113.3M
Gross Profit
95.6M
84.39%
Operating Income
14.4M
12.73%
Net Income
19.5M
17.19%
EPS (Diluted)
$0.08
Balance Sheet Metrics
Total Assets
709.9M
Total Liabilities
346.4M
Shareholders Equity
363.5M
Debt to Equity
0.95
Cash Flow Metrics
Operating Cash Flow
28.1M
Free Cash Flow
18.5M
Revenue & Profitability Trend
Cellebrite DI Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 401.2M | 325.1M | 270.7M | 246.2M | 194.9M |
Cost of Goods Sold | 62.6M | 53.2M | 50.7M | 42.6M | 37.9M |
Gross Profit | 338.6M | 271.9M | 219.9M | 203.7M | 157.0M |
Gross Margin % | 84.4% | 83.6% | 81.3% | 82.7% | 80.6% |
Operating Expenses | |||||
Research & Development | 98.4M | 84.4M | 80.6M | 65.5M | 54.4M |
Selling, General & Administrative | 183.3M | 154.3M | 138.2M | 124.3M | 93.4M |
Other Operating Expenses | - | - | - | - | 689.0K |
Total Operating Expenses | 281.7M | 238.6M | 218.9M | 189.9M | 148.5M |
Operating Income | 56.9M | 33.2M | 1.0M | 13.8M | 9.2M |
Operating Margin % | 14.2% | 10.2% | 0.4% | 5.6% | 4.7% |
Non-Operating Items | |||||
Interest Income | 18.2M | 8.9M | 1.6M | 847.0K | 2.7M |
Interest Expense | 29.0K | 141.0K | 149.0K | 153.0K | 0 |
Other Non-Operating Income | -1.3M | 206.0K | 845.0K | -194.0K | -446.0K |
Pre-tax Income | -276.0M | -75.6M | 120.8M | 82.3M | 11.4M |
Income Tax | 7.0M | 5.5M | -45.0K | 10.9M | 5.6M |
Effective Tax Rate % | 0.0% | 0.0% | -0.0% | 13.3% | 49.3% |
Net Income | -283.0M | -81.1M | 120.8M | 71.4M | 5.8M |
Net Margin % | -70.5% | -24.9% | 44.6% | 29.0% | 3.0% |
Key Metrics | |||||
EBITDA | -264.0M | -65.6M | 129.3M | 89.7M | 17.7M |
EPS (Basic) | $-1.35 | $-0.43 | $0.64 | $0.49 | $-0.05 |
EPS (Diluted) | $-1.35 | $-0.43 | $0.59 | $0.44 | $-0.05 |
Basic Shares Outstanding | 209471827 | 190154549 | 182693375 | 144002394 | 187168729 |
Diluted Shares Outstanding | 209471827 | 190154549 | 182693375 | 144002394 | 187168729 |
Income Statement Trend
Cellebrite DI Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 191.7M | 189.5M | 87.6M | 146.0M | 128.7M |
Short-term Investments | 255.6M | 113.4M | 96.0M | 35.6M | 108.9M |
Accounts Receivable | 82.4M | 77.3M | 78.8M | 67.5M | 66.3M |
Inventory | 8.9M | 9.9M | 10.2M | 6.5M | 4.8M |
Other Current Assets | 12.4M | 16.9M | 8.5M | 3.1M | 3.0M |
Total Current Assets | 567.6M | 422.1M | 295.9M | 273.2M | 324.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 11.2M | 14.8M | 16.2M | 526.0K | 509.0K |
Goodwill | 68.7M | 64.3M | 64.9M | 64.9M | 25.5M |
Intangible Assets | 11.3M | 10.6M | 11.3M | 11.2M | 6.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 18.8M | 14.4M | 14.2M | 11.8M | 7.9M |
Total Non-Current Assets | 123.0M | 110.8M | 107.4M | 66.6M | 40.1M |
Total Assets | 690.6M | 532.9M | 403.3M | 339.8M | 364.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 11.1M | 8.3M | 4.6M | 9.5M | 4.7M |
Short-term Debt | 4.1M | 5.0M | 5.0M | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 295.5M | 253.8M | 207.8M | 186.6M | 159.4M |
Non-Current Liabilities | |||||
Long-term Debt | 6.8M | 9.2M | 10.4M | 0 | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 7.0M | 134.5M | 49.1M | 133.7M | 6.2M |
Total Non-Current Liabilities | 59.0M | 244.8M | 121.7M | 226.6M | 141.2M |
Total Liabilities | 354.5M | 498.7M | 329.4M | 413.1M | 300.6M |
Equity | |||||
Common Stock | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -164.9M | 118.1M | 199.2M | 78.4M | 28.3M |
Treasury Stock | 85.0K | 85.0K | 85.0K | 85.0K | 85.0K |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 336.0M | 34.2M | 73.9M | -73.3M | 63.8M |
Key Metrics | |||||
Total Debt | 11.0M | 14.1M | 15.4M | 0 | 0 |
Working Capital | 272.1M | 168.3M | 88.2M | 86.6M | 164.9M |
Balance Sheet Composition
Cellebrite DI Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -283.0M | -81.1M | 120.8M | 71.4M | 5.8M |
Depreciation & Amortization | 10.6M | 10.0M | 9.2M | 7.0M | 5.9M |
Stock-Based Compensation | 30.6M | 19.0M | 13.7M | 6.5M | 7.3M |
Working Capital Changes | 21.3M | 47.0M | 11.7M | 23.9M | 26.9M |
Operating Cash Flow | 3.6M | 77.5M | 72.0M | 51.2M | 43.7M |
Investing Activities | |||||
Capital Expenditures | -8.6M | -5.2M | -6.9M | -5.1M | -6.2M |
Acquisitions | -2.7M | 0 | 0 | -20.0M | -15.0M |
Investment Purchases | -334.8M | -144.3M | -165.4M | -21.0M | -138.5M |
Investment Sales | 198.7M | 129.7M | 83.2M | 94.3M | 153.3M |
Investing Cash Flow | -147.4M | -19.9M | -89.0M | 48.2M | -6.4M |
Financing Activities | |||||
Share Repurchases | - | - | 0 | 0 | -85.0K |
Dividends Paid | - | 0 | 0 | -100.0M | -10.0M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -11.0K | 0 | 0 | -70.7M | -8.6M |
Free Cash Flow | 121.6M | 94.1M | 11.5M | 27.9M | 60.3M |
Net Change in Cash | -143.8M | 57.7M | -17.1M | 28.7M | 28.7M |
Cash Flow Trend
Cellebrite DI Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
69.09
Forward P/E
39.88
Price to Book
9.55
Price to Sales
8.93
PEG Ratio
39.88
Profitability Ratios
Profit Margin
-34.56%
Operating Margin
14.58%
Return on Equity
-81.98%
Return on Assets
5.95%
Financial Health
Current Ratio
1.96
Debt to Equity
5.47
Beta
1.27
Per Share Data
EPS (TTM)
$-0.72
Book Value per Share
$1.67
Revenue per Share
$1.90
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
clbt | 3.9B | 69.09 | 9.55 | -81.98% | -34.56% | 5.47 |
Microsoft | 3.8T | 39.67 | 11.86 | 33.61% | 35.79% | 32.63 |
Oracle | 654.9B | 53.72 | 32.00 | 82.38% | 21.68% | 519.59 |
Amdocs | 9.5B | 17.53 | 2.72 | 15.73% | 11.94% | 23.65 |
Klaviyo | 9.8B | -192.76 | 8.95 | -6.42% | -6.19% | 9.04 |
Shift4 Payments | 8.0B | 33.82 | 9.84 | 18.28% | 6.11% | 186.68 |
Financial data is updated regularly. All figures are in the company's reporting currency.